Location History:
- Cheonan-si, KR (2011)
- Gyeonggi-do, KR (2015 - 2018)
Company Filing History:
3 out of 49 
1 out of 131,611 
Years Active: 2011-2018
Title: Hyun-Mo Yang: Innovator in Histone Deacetylase Inhibitors
Introduction
Hyun-Mo Yang is a prominent inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of selective histone deacetylase (HDAC) inhibitors. With a total of four patents to his name, Yang's work is pivotal in addressing various diseases.
Latest Patents
Yang's latest patents include innovative compounds that serve as selective histone deacetylase inhibitors. One of his notable inventions involves urea derivatives that exhibit HDAC inhibitory activity. These compounds are effective in treating histone deacetylase-mediated diseases such as malignant tumors, inflammatory diseases, rheumatoid arthritis, and neurodegeneration. Another significant patent features novel azaindole derivatives, which also possess HDAC inhibitory activity. These azaindole derivatives can be utilized in pharmaceutical compositions aimed at treating similar diseases.
Career Highlights
Throughout his career, Hyun-Mo Yang has worked with reputable companies, including Chong Kun Dang Pharmaceutical Corporation and Samsung Electronics Co., Ltd. His experience in these organizations has contributed to his expertise in pharmaceutical innovation and development.
Collaborations
Yang has collaborated with notable colleagues, including ChangSik Lee and Soyoung Kim. These partnerships have likely enhanced his research and development efforts in the pharmaceutical field.
Conclusion
Hyun-Mo Yang's contributions to the development of selective histone deacetylase inhibitors are significant in the realm of pharmaceuticals. His innovative patents and collaborations reflect his commitment to advancing medical treatments for various diseases.